Eli Lilly has struck a massive deal with South Korea’s biotech firm ABL Bio, committing $40 million upfront and up to $2.56 billion in milestones to jointly develop bispecific antibodies using ABL Bio’s proprietary Grabody platform including blood-brain-barrier (BBB) penetrating therapies.
Glimpse:
Under the agreement, Lilly will license ABL Bio’s Grabody-B technology to create novel bispecific antibodies for neurological and systemic diseases. ABL Bio will receive $40 million immediately, plus nearly $2.56 billion in development and commercial milestones, along with royalties. The deal also involves a separate equity investment by Lilly.
Strategic Licensing and Research Pact
Eli Lilly has entered into a landmark licensing and joint-research agreement with ABL Bio, a Seoul-based biotech company specializing in bispecific antibodies. The deal centers on ABL Bio’s Grabody-B platform, which is capable of delivering therapies across the blood-brain barrier (BBB), a major hurdle in neurological drug delivery. Under the terms, ABL Bio will receive a $40 million upfront payment, with the potential for as much as $2.56 billion in development, regulatory, and commercialization milestones.
Equity Investment by Lilly
In addition to the licensing deal, Lilly is making a strategic equity investment in ABL Bio. The company will acquire newly issued common shares worth 22 billion KRW (roughly $15 million), subject to regulatory clearances. This move aligns Lilly’s financial interests closely with ABL Bio’s long-term success, deepening their collaboration beyond just research.
Expanding Platform Indications
ABL Bio plans to expand the use of its Grabody platform beyond neurological disorders. According to CEO Lee Sang-hoon, the company intends to apply the technology to systemic diseases, including obesity and muscle disorders. This expansion could unlock broader therapeutic areas, enhancing the commercial potential of the platform.
Strategic & Scientific Impact
For Lilly, this is a major bet on next-generation antibody therapeutics. The Grabody technology’s BBB-penetrating capability could transform treatment for neurodegenerative diseases. For ABL Bio, this deal not only provides significant capital but also validation from a top-tier global pharma, positioning it as a serious player in the bispecific antibody space. The collaboration is further reinforced by a legal advisory from Wilson Sonsini, highlighting both the scale and strategic depth of the transaction.
“This agreement is a turning point for ABL Bio leveraging our Grabody platform together with Lilly opens the door to transformative therapies for hard-to-reach targets.”
By
HB Team
